Ribavirin tablet is contraindicated in:
Patients with known hypersensitivity to ribavirin tablets or to any component of the tablet.
Women who are pregnant.
Men whose female partners are pregnant.
Patients with hemoglobinopathies (e.g., thalassemia major or sickle-cell anemia).
Ribavirin tablets and peginterferon alfa-2a combination therapy is contraindicated in patients with:
Hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during treatment.
Hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment.